Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 86 - Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameBoard of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer InstituteAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number86
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/bsc/cse/cse...
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*30
Current Charter Date9/30/1994Designated Fed Officer Position Title*Chief, Institute Review Office, NCI
Date Of Renewal Charter Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Mehrdad
Exempt From Renewal*YesDesignated Federal Officer Middle NameM.
Specific Termination AuthorityDesignated Federal Officer Last Name*Tondravi
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPh.D.
Specific Establishment Authority*42 U.S.C. 284(c)(3)Designated Federal Officer Phone*(240) 276-5660
Effective Date Of Authority*11/4/1988Designated Federal Officer Fax*(240) 276-7912
Exempt From EO 13875 Discretionary CmteExempt: Merit Review PanelDesignated Federal Officer Email*tondravim@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Other Committee
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*This committee is composed of recognized biomedical and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide evaluation and peer review of Institute laboratories and staff scientists in the Center for Cancer Research and the Division of Cancer Epidemiology and Genetics.
How is membership balanced?*The Board consists of up to thirty members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research; clinical cancer treatment; cancer etiology; cancer prevention and control with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis; cancer biology and diagnosis; cancer center administration; medicine; radiological and surgical oncology; cancer chemotherapy; cancer epidemiology, genetics, genomics, and related areas; cancer education; cancer information services; community outreach; biological, chemical and physical carcinogenesis; DNA repair; tumor biology and immunology; humoral and cellular immunity; hematopoiesis; cell differentiation and transformation; oncogenes and growth factors; molecular and structural biology; genetic regulation; cell signaling; viral oncology; vaccine development; transplantation; clinical trial design, management and evaluation; pharmacology; drug development and developmental therapeutics; proteomics; genetic and immunotherapies; pathology; diagnostic research and cytogenetics; biological response modifiers; imaging; nutrition; survey research; epidemiology; biostatistics; statistics; rehabilitation; psychology and behavioral medicine; public health and community oncology; quality of life; pain management; cancer detection and diagnosis; cancer treatment and restorative care; dentistry; nursing; public health; education of health professionals; medical oncology; surgery; radiotherapy; gynecologic oncology; and pediatric oncology.
How frequent & relevant are cmte mtgs?*The Board meets approximately three times each fiscal year. The Board met on November 4, 2019, March 10, 2020, and July 13, 2020 for the overall program review of all Laboratories and Branches. The November 4, 2019 meeting was partially closed. During the open session the Division of Cancer Epidemiology and Genetics (DCEG) presented one Research & Development (R&D) Contract Proposal for Concept Review. Dr. Stephen Chanock, Scientific Director, DCEG presented the Division-wide R&D Support contract proposal to the BSC for a concept review. The concept is to support filed activities, biospecimen collection and processing and clinical activities of all DCEG investigators. The Board approved the concept unanimously. Special site visit teams met two times to review and evaluate the program of individual laboratories and branches and advise on budget, staffing, and program strengths and weaknesses. Site Visit Dates: 12/04/2019 and 02/21/2020.
Why advice can't be obtained elsewhere?*This Board is composed of recognized biomedical and behavioral research authorities from outside the NIH in order to secure unbiased and objective evaluations of intramural research programs. Their recommendations are invaluable because the complex nature of research in each laboratory requires a unique balance and breadth of expertise not available at NIH or from other established sources. This advice is essential for effective management of this Institute's intramural research programs.
Why close or partially close meetings?The meetings of this Board were closed to the public for the review, discussion, and evaluation of individual programs and projects conducted by the Divisions including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Section 552b(c)(6) of the Government in the Sunshine Act permits the closing of meetings where discussions could reveal personal information, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Recommendation RemarksCommittee Function: Other - Scientific and Technical Peer Review.

Reports: This committee did not produce any public reports.

Members: The terms for Patricia M. Lorusso, Roman Perez-Soler, Joan H. Schiller, and Sally W. Vernon have changed due to administration extensions. Julie E. Buring has been reappointed. As such, their terms of service end dates are different than what was reported on the FY19 ACR. The term for Julie Buring is longer than the charter allows due to their reappointment to the BSC C&E given her specific scientific expertise and the need to assure continuity in the functions of the BSC C&E and the review of Laboratories/Branches by the Board.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentThe Scientific Director and other NIH/NCI officials use the recommendations made by the BSC in evaluating the quality of the intramural research programs including scientific priorities and resources available. As a result, all the Laboratories/Branches reviewed in this fiscal year were either continued, expanded or closed.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentAlthough grant reviews are included in the duties of this Board, there were no grant reviews performed during this fiscal year.
Number Of Recommendations*372Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentAll the Laboratories/Branches reviewed in this fiscal year were either continued, expanded or closed. Continued means that there is not a change in scientific priorities or a decrease in the resources allocated to the laboratory/branch. Expanded means that the scientific priorities may be/are increased and thus an increase in resources are allocated to the laboratory/branch. Closed means that the scientific priorities are ended and the resources allocated to the laboratory/branch are decreased, i.e., towards closing the laboratory/branch.Access Agency WebsiteYes
% of Recs Fully Implemented*90.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsNo
% of Recs Partially Implemented CommentThe percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*The Division Director provides a follow-up report to the Board for every Lab/Branch/Principal Investigator that was site visited in the fiscal year and the specific action taken as a result of the Board recommendations.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by conducting research in its own laboratories. Section 402(b)(3) of the Public Health Service Act states that “the Director, NIH...shall assure that research at...the National Institutes of Health is subject to review in accordance with section 492.” Section 492(b) states that the “Director of NIH shall establish procedures for periodic technical and scientific peer review of research at the National Institutes of Health. The mission of the Board of Scientific Counselors is to assess the quality of the Institute’s intramural research programs and to evaluate the productivity and performance of intramural scientists and shall also, as requested by the Director, NIH, undertake peer review of extramural funding applications as required by section 492 of the Public Health Service Act, as amended."
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$15,200.00Est Payments to Non-Fed Members Next FY*$15,200.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$477,381.00Estimated Payments to Federal Staff*$489,793.00
Payments to Consultants*$13,200.00Est. Payments to Consultants Next FY*$13,200.00
Travel Reimb. For Non-Federal Members*$23,419.00Est Travel Reimb Non-Fed Members nextFY*$23,550.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$23,015.00Est Travel Reimb to Consultants Next FY*$23,133.00
Other Costs$4,174.00Est. Other Costs Next FY*$4,216.00
Total Costs$556,389.00Est. Total Next FY*$569,092.00
Federal Staff Support (FTE)*2.80Est. Fed Staff Support Next FY*2.80
Cost RemarksDue to the COVID-19 pandemic, FY2020 meetings held after March 12, 2020 were virtual only, which reduced committee operating costs. If face to face meetings resume, committee costs for FY2021 may be higher.Est Cost Remarks
Hide Section - Interest Areas

Interest Areas

Category
Area
Medicine
Diseases
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036582Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2019
 COM-034799Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2018
 COM-001884Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2017
 COM-002685Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2016
 COM-004003Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2015
 COM-004480Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2014
 COM-006254Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2013
 COM-006957Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2012
 COM-007963Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2011
 COM-008685Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2010
 COM-010310Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2009
 COM-011019Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2008
 COM-011924Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2007
 COM-012603Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2006
 COM-013958Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute2005
 COM-014487Board of Scientific Counselors, National Cancer Institute2004
 COM-015704Board of Scientific Counselors, National Cancer Institute2003
 COM-016780Board of Scientific Counselors, National Cancer Institute2002
 COM-017668Board of Scientific Counselors, National Cancer Institute2001
 COM-018367Board of Scientific Counselors, National Cancer Institute2000
 COM-019583Board of Scientific Counselors, National Cancer Institute1999
 COM-020444Board of Scientific Counselors, National Cancer Institute1998
 COM-021689Board of Scientific Counselors, National Cancer Institute1997